Skip to Main Content
U.S. Department of Health & Human Services » National Institutes of Health
National Heart, Lung, and Blood Institute
Login | Register

Biologic Specimen and Data Repository Information Coordinating Center

  • Home (current)
  • About BioLINCC
    • About Us
    • FAQ
    • Contact Us
    • Glossary
  • Biospecimen and Data Resources
    • Overview
    • Studies
    • Teaching Datasets - Public Use Datasets
    • Renew Existing Data Use Agreement
    • Publications
    • Funding Opportunities
    • Non-BioLINCC Resources
    • Covid-19 Resources
  • Procedures and Forms
    • BioLINCC Handbook
    • Form Templates
    • Agreement Templates
  • Build/Submit New Collection
    • NHLBI Biorepository Guide
    • Submit Datasets
    • Submit Biospecimens and Datasets
Home > Studies > Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

Note that you will be prompted to log in or register an account

Accession Number
HLB00620808a

Study Type
Clinical Trial

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
November 1995 - June 2005

NHLBI Division
DCVS

Dataset(s) Last Updated
January 3, 2018

Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00000558

Primary Publication URLs
https://www.ncbi.nlm.nih.gov/pubmed/15531767

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research No

Commercial Use Specimen Restrictions No

Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes

Genetic Use Of Specimens Allowed? Yes

Genetic Use Area Of Research Restrictions Yes

Specific Consent Restrictions
Consent restricts use of biospecimens to research related to predictors of coronary heart disease progression.

Objectives

To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.

Background

Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

Subjects

The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

Conclusions

In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)

Additional Details

Study Population

Subjects:

Placebo: 4,132

Active Drug, Trandolapril: 4,158

Age:

 

Placebo

Active drug, trandolapril

All

N

%

N

%

N

%

46-50

91

2.20

94

2.26

185

2.23

51-55

610

14.76

629

15.13

1239

14.95

56-60

781

18.90

733

17.63

1514

18.26

61-65

817

19.77

803

19.31

1620

19.54

66-70

795

19.24

868

20.88

1663

20.06

71-75

621

15.03

620

14.91

1241

14.97

76-80

349

8.45

332

7.98

681

8.21

>=81

68

1.65

79

1.90

147

1.77

 
Sex:
 

 

Placebo

Active drug, trandolapril

All

N

%

N

%

N

%

Female

704

17.04

790

19.00

1494

18.02

Male

3428

82.96

3368

81.00

6796

81.98

 

Available Biospecimens

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Visits (Vials):

03/04/2019

  Serum Plasma Urine Total
Baseline 7,354 21,255 6,712 35,321
Follow-up Visit 1 55 79 35 169
Follow-up Visit 2 1,244 1,561 724 3,529
Follow-up Visit 3 701 889 388 1,978
Follow-up Visit 4 1,823 2,312 1,002 5,137
Follow-up Visit 5 1,017 1,276 545 2,838
Follow-up Visit 6 2,820 3,517 1,546 7,883
Follow-up Visit 7 1,274 1,644 675 3,593
Follow-up Visit 8 2,220 2,783 1,232 6,235
Follow-up Visit 9 427 561 230 1,218
Follow-up Visit 10 423 585 238 1,246
Follow-up Visit 11 110 154 57 321
Follow-up Visit 12 29 38 18 85
Unknown 1,511 2,097 736 4,344

 
Visits (Subjects):

03/04/2019

  Serum
Total number of subjects Average volume (ml) per subject
Baseline 3,701 0.99
Follow-up Visit 1 13 2.12
Follow-up Visit 2 251 2.48
Follow-up Visit 3 141 2.49
Follow-up Visit 4 369 2.49
Follow-up Visit 5 207 2.49
Follow-up Visit 6 571 2.47
Follow-up Visit 7 258 2.49
Follow-up Visit 8 450 2.48
Follow-up Visit 9 86 2.67
Follow-up Visit 10 86 2.63
Follow-up Visit 11 22 2.50
Follow-up Visit 12 6 2.42
Unknown 306 2.48
 
  Plasma
Total number of subjects Average volume (ml) per subject
Baseline 3,770 1.94
Follow-up Visit 1 13 2.98
Follow-up Visit 2 251 3.17
Follow-up Visit 3 140 3.25
Follow-up Visit 4 368 3.13
Follow-up Visit 5 208 3.03
Follow-up Visit 6 573 3.12
Follow-up Visit 7 260 3.24
Follow-up Visit 8 450 3.23
Follow-up Visit 9 87 3.58
Follow-up Visit 10 86 3.50
Follow-up Visit 11 22 3.76
Follow-up Visit 12 6 2.83
Unknown 306 3.48
 
  Urine
Total number of subjects Average volume (ml) per subject
Baseline 3,367 11.32
Follow-up Visit 1 12 14.58
Follow-up Visit 2 242 14.96
Follow-up Visit 3 130 14.92
Follow-up Visit 4 335 14.96
Follow-up Visit 5 184 14.81
Follow-up Visit 6 516 14.98
Follow-up Visit 7 225 15.00
Follow-up Visit 8 413 14.92
Follow-up Visit 9 77 14.94
Follow-up Visit 10 80 14.88
Follow-up Visit 11 19 15.00
Follow-up Visit 12 6 15.00
Unknown 244 15.30

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens and Study Datasets

Study Catalog

Study Publications (35)

Materials Available

  • Plasma
  • Serum
  • Urine
  • More Details

Study Documents

  • PDF Data Dictionary (PDF - 84.3 KB)
  • PDF Data Dictionary Ancillary (PDF - 46.4 KB)
  • PDF Follow-up Visit (PDF - 120.6 KB)
  • PDF List of Publications (PDF - 84.4 KB)
  • PDF Pre-Randomization Information (PDF - 107.4 KB)
  • PDF Protocol (PDF - 126.4 KB)
  • PDF Randomization Visit (PDF - 142.4 KB)
  • PDF Screening Form (PDF - 125.0 KB)
  • PDF PEACE LADS Readme (PDF - 377.2 KB)
  • Ancillary Study Documentation

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

  • About Us
  • FAQ
  • Glossary
  • Contact
  • Privacy Policy
  • Accessibility
  • FOIA
  • HHS Vulnerability Disclosure

  • U.S. Department of Health & Human Services
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • USA.gov
NIH… Turning Discovery Into Health®